Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
Stephen D. Wiviott(Brigham and Women's Hospital), Elliott M. Antman(Brigham and Women's Hospital), Gilles Montalescot(Maastricht University Medical Centre), Witold Rużyłło(Institute of Cardiology), Diego Ardissino(University of Leeds), Shmuel Gottlieb(Bikur Cholim Hospital), Stefano De Servi(University of Pavia), Govinda J. Weerakkody(Eli Lilly (United States)), Sabina A. Murphy(Brigham and Women's Hospital), Carolyn H. McCabe(Brigham and Women's Hospital), Jeffrey Riesmeyer(Eli Lilly (United States)), C. Michael Gibson(Baim Institute for Clinical Research), F.-J. Neumann(Universitäts-Herzzentrum Freiburg-Bad Krozingen), Eugene Braunwald(Mass General Brigham)
Cited by 6,743
Related Papers
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
|New England Journal of Medicine|2017|6k
Edoxaban versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2013|5.1k
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
|Journal of the American College of Cardiology|2020|2.9k
Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction
|New England Journal of Medicine|2015|2k